Developers are increasingly relying on large language models (LLMs) for everyday computing tasks such as fixing bugs, ...

VANCOUVER, BC / ACCESS Newswire / July 7, 2026 /Trans Canada Gold Corp. (TSXV:TTG)(OTCQB:TTGXF) ("Trans Canada" or the "Company") is pleased to announce that the Company has successfully mobilized its ...

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program. KT-621 parallel Phase 2b trials advancing in AD and asthma, with data e ...

The Ankara summit may mark the birth of NATO 3.0, reshaping the alliance's strategy and elevating Türkiye's strategic role ...

What constrains distributed systems isn’t access, but execution. With autonomous data movement and action occurring at ...

Angela’s progress reflects the broader purpose of cancer rehabilitation at Levine Cancer: helping patients manage the ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

Dr. Michael C. Threatt urges Habitat for Humanity to partner with PHAs to expand HCV Homeownership nationwide, ...

With political endorsements and artificial intelligence demand converging, market participants must evaluate the underlying ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases, today announced that an abstract featuring new clinical data on ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 ...